Cooperative Agreement W81XWH1720009

This Project Grant award of $350,000 from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, supports the development of a novel anti-fibrotic compound platform by Adiutrix Therapeutics LLC. The goal is to identify and develop first-in-class therapeutics targeting collagen prolyl-4 hydroxylase (C-P4H), an enzyme responsible for collagen maturation, to treat fibrotic diseases such as idiopathic pulmonary fibrosis, scleroderma, and kidney/intestinal fibrosis. The...

The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program. The goal of this 17-month grant is to develop and commercialize a novel, safer, and more effective therapy for the treatment of idiopathic pulmonary fibrosis (IPF) and other causes of progressive pulmonary fibrosis. Novomedix has developed a series of small molecule compounds that inhibit myofibroblast activation and...

This $560,000 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), aims to develop a novel triple gene therapy approach to treat ischemic heart failure. The research team at Baylor College of Medicine, the prime awardee, will conduct preclinical testing to determine the optimal dosage and evaluate the efficacy and initial safety of this triple therapy in animal models and human heart slices....

The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $805,845 to the Proteogenomics Research Institute for Systems Medicine in La Jolla, CA to develop novel lung-targeted therapies for treating lung fibrosis. The key products and services to be delivered under this four-year grant include: 1) generating and testing in vitro the efficacy of therapeutics that target caveolae in...

This $389,754 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is supporting research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The research aims to evaluate the peptide's efficacy in reducing fibrosis in a murine model, as well as conduct pilot toxicity, pharmacokinetic, and biodistribution analyses....

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $571,404.00 to the University of Pittsburgh to conduct research aimed at understanding and improving neurological outcomes after traumatic brain injury (TBI). The key research objectives are to: Evaluate the long-term therapeutic potential of an adiponectin receptor agonist in...

This $884,888 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports research at Brigham & Women's Hospital to investigate the molecular mechanisms by which sex hormones, particularly testosterone and estradiol, modulate wound healing. The key objectives of this 18-month research project are to: 1) develop improved in vitro models to study how sex hormones affect wound cell behavior; 2)...

The University of Pittsburgh is receiving a $437,250 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant aims to provide proof-of-concept evidence that retinoic acid (RA) can attenuate cholinergic deficits and white matter connectivity impairments after traumatic brain injury (TBI). The two-year project will: 1) determine if RA treatment...

This $1,193,262 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to advance a novel adeno-associated virus (AAV)-mediated gene therapy for the treatment of idiopathic pulmonary fibrosis (IPF). The research team at the University of California, San Francisco (UCSF) will rigorously validate the efficacy of the AAV-SGPL1 gene therapy in IPF mouse models and lung tissue samples. Specifically, they...